MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Oncimmune shares plummet as interim revenue falls by fifth

ALN

Oncimmune Holdings PLC on Wednesday said revenue was down in the first half of its financial year due to delivery delays, but its loss narrowed.

Oncimmune shares were down 32% to 25.00 pence each in London on Wednesday afternoon. The stock is down 74% over the past 12 months.

Oncimmune is a Nottingham, England-based immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases.

The company reported revenue of £1.1 million in the financial half-year ended February 28, down 21% from £1.4 million in the first half of financial 2022, ended November 20, 2021. Oncimmune noted that delays in sample deliveries from major contracts delayed revenue into the second half of the year.

In August last year, Oncimmune changed its financial year-end to August from May.

Oncimmune said pretax loss was £4.1 million in the recent six months, narrowing from £4.9 million a year prior. The company said that it expects to benefit from lower operating costs following its sale of Oncimmune Ltd earlier this month.

Earlier this month, the company sold Oncimmune Ltd and Oncimmune Europe GmbH to Freenome Holdings Inc for £13 million.

Looking ahead, Oncimmune said it has ‘significant near-term growth prospects’.

Chief Executive Adam Hill said: ‘The sale of Oncimmune Ltd to Freenome not only allows for a singular focus on building value in our ImmunoInsights platform, but also is a lead indicator of renewed confidence in the UK life-science sector after a period of significant under investment.

‘It remains my firm belief that this platform has the potential to offer significant value to our customers, and is primed to respond, at scale, in lockstep with the market as it inevitably rebounds. Post the sale of the Oncimmune Ltd, our focus is the expansion of the ImmunoInsights services business with an intention to achieve a cash flow break even position in the near term.’

Copyright 2023 Alliance News Ltd. All Rights Reserved.